secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2022-09-26T23:59:59+00:00
Accession:  0001493152-22-026840
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell Therapeutics amends employment agreements and adopts bonus plan
----------------------------------------------------------------------------

- New employment agreements set salaries: CEO $690k, GC $394.8k, SVP $366.8k; bonus targets 55%, 40%, 35% respectively.
- Termination benefits enhanced: CEO receives 12 months salary + 100% bonus (18 months + 150% on change of control); others receive 9 months + pro-rata (12 months + 100% on change of control).
- New Executive Performance Incentive Bonus Plan adopted; bonuses tied to financial, clinical, and operational goals determined by Compensation Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000149315222026840/0001493152-22-026840-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000149315222026840/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-026840

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer